A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Trial Profile

A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Tecemotide (Primary) ; Carboplatin; Cyclophosphamide; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Dec 2017 Planned primary completion date changed from 1 Jan 2016 to 30 Jun 2018.
    • 20 Oct 2017 Status changed from recruiting to active, no longer recruiting.
    • 12 Sep 2014 Merck KGaA has discontinued its development of tecemotide for the treatment of non-small cell lung cancer based on disappointing trial results. The status of this trial is unclear, following this decision.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top